

**Van:** [CCMO - Bevoegde Instantie / Competent Authority](#)  
**Aan:** [ccmo\\_frontoffice](#)  
**Cc:** [ccmo\\_eudract](#)  
**Onderwerp:** FW: NL67312.028.18: Notification End of Trial  
**Datum:** vrijdag 11 december 2020 20:13:34  
**Bijlagen:** [A1. CA Global EoT Cover Letter\\_11Dec2020.pdf](#)  
[B3. EudraCT Application Form dd 11Dec2020.pdf](#)  
[B7. EudraCT End Of Trial dd 11Dec2020.pdf](#)

---

Voor Marjolein en voor EudraCT

5.1.2.e

---

**Van:** PPD Netherlands (SM) <PPDNetherlands.SM@ppdi.com>  
**Verzonden:** vrijdag 11 december 2020 09:14  
**Aan:** CCMO - Bevoegde Instantie / Competent Authority <bi@ccmo.nl>  
**CC:** 5.1.2.e <5.1.2.e@ppdi.com>  
**Onderwerp:** NL67312.028.18: Notification End of Trial

**Re:** **Digital submission of End of Trial**  
**Protocol:** **PVO-2A-201**  
**EudraCT number:** **2017-002751-28**  
**NL number:** **NL67312.028.18**

Dear members of the Central Committee on Research Involving Human Subjects,

With this letter we would like to inform the Competent Authority (Central Committee on Research Involving Human Subjects) that the research entitled: *"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas"* registered under number NL67312.028.18 has ended globally.

Please find attached to this email the full cover letter as well as supporting documents:

- A1. Cover letter Cover letter NL67312.028.18 dd 11Dec2020
- B3. EudraCT Application Form dd 11Dec2020
- B7. EudraCT End of Trial Form dd 11Dec2020

Please address any enquiries to undersigned.

Thank you in advance.

Met vriendelijke groet / Kind regards,

5.1.2.e

5.1.2.e

Clinical Monitoring, Clinical Operations

*Working days: Monday, Tuesday, and Thursday*

PPD  
Landgoed de Born  
Bornweg 12C  
6721 AH Bennekom  
The Netherlands

**Phone** +31 (0) 318 655.1.2.e  
**Mobile** +31 (0) 6 5.1.2.e  
**Fax** +31 (0) 318 655.1.2.e  
**e-mail** 5.1.2.e@ppdi.com  
**Web site** [www.ppd.com](http://www.ppd.com)

This email transmission and any documents, files or previous email messages attached to it may contain information that is confidential or legally privileged. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you are hereby notified that you must not read this transmission and that any disclosure, copying, printing, distribution or use of this transmission is strictly prohibited. If you have received this transmission in error, please immediately notify the sender by telephone or return email and delete the original transmission and its attachments without reading or saving in any manner.